| Literature DB >> 27731647 |
Grazia Chiellini1, Giulia Nesi2, Simona Sestito2, Sara Chiarugi2, Massimiliano Runfola2, Stefano Espinoza3, Martina Sabatini1, Lorenza Bellusci1, Annunziatina Laurino4, Elena Cichero5, Raul R Gainetdinov6,7, Paola Fossa5, Laura Raimondi4, Riccardo Zucchi1, Simona Rapposelli2.
Abstract
The trace amine-associated receptor 1 (TAAR1) is a G-protein-coupled receptors (GPCR) potently activated by a variety of molecules besides trace amines (TAs), including thyroid hormone-derivatives like 3-iodothyronamine (T1AM), catechol-O-methyltransferase products like 3-methoxytyramine, and amphetamine-related compounds. Accordingly, TAAR1 is considered a promising target for medicinal development. To gain more insights into TAAR1 physiological functions and validation of its therapeutic potential, we recently developed a new class of thyronamine-like derivatives. Among them compound SG2 showed high affinity and potent agonist activity at mouse TAAR1. In the present work, we describe design, synthesis, and SAR study of a new series of compounds (1-16) obtained by introducing specific structural changes at key points of our lead compound SG2 skeleton. Five of the newly synthesized compounds displayed mTAAR1 agonist activity higher than both SG2 and T1AM. Selected diphenylmethane analogues, namely 1 and 2, showed potent functional activity in in vitro and in vivo models.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27731647 DOI: 10.1021/acs.jmedchem.6b01092
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446